Pages that link to "Q44759324"

The following pages link to Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. (Q44759324):

Displaying 44 items.

• In vitro pharmacokinetics of anti-psoriatic fumaric acid esters (Q24791666) (← links)
• Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy (Q26738969) (← links)
• Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases (Q28078742) (← links)
• Development of oral immunomodulatory agents in the management of multiple sclerosis (Q28388704) (← links)
• Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse (Q28750219) (← links)
• Effects of monomethylfumarate on dendritic cell differentiation. (Q34564447) (← links)
• Fumaric Acid and its esters: an emerging treatment for multiple sclerosis (Q34611373) (← links)
• Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. (Q34627230) (← links)
• Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview (Q34667496) (← links)
• The antipsoriatic agent monomethylfumarate has antiproliferative, prodifferentiative, and anti-inflammatory effects on keratinocytes. (Q34785582) (← links)
• Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). (Q35181833) (← links)
• Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells (Q35441339) (← links)
• The effects of fumaria parviflora L extract on chronic hand eczema: a randomized double-blind placebo controlled clinical trial (Q36022210) (← links)
• Vitamin D₃ and monomethyl fumarate enhance natural killer cell lysis of dendritic cells and ameliorate the clinical score in mice suffering from experimental autoimmune encephalomyelitis. (Q36329622) (← links)
• Emerging drugs for psoriasis (Q36634244) (← links)
• The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder (Q36653650) (← links)
• The multicomponent medication lymphomyosot improves the outcome of experimental lymphedema (Q36968316) (← links)
• Psoriasis: advances in pathophysiology and management (Q36995858) (← links)
• Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy (Q37122279) (← links)
• Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies (Q37318146) (← links)
• Angiogenesis drives psoriasis pathogenesis (Q37534974) (← links)
• Emerging oral drugs for relapsing-remitting multiple sclerosis. (Q37965547) (← links)
• Drugs in development for relapsing multiple sclerosis (Q38101004) (← links)
• Dimethyl fumarate : a Janus-faced substance? (Q38108633) (← links)
• Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis (Q38127463) (← links)
• Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects (Q38141840) (← links)
• Advances in treating psoriasis (Q38193099) (← links)
• Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis (Q38202636) (← links)
• Dimethyl fumarate for treating relapsing multiple sclerosis (Q38266397) (← links)
• Toll-Like Receptor Pathways in Autoimmune Diseases (Q38357504) (← links)
• Oxidative stress in multiple sclerosis: Central and peripheral mode of action (Q38655679) (← links)
• Anti-Psoriatic Drug Monomethylfumarate Increases Nuclear Factor Erythroid 2-Related Factor 2 Levels and Induces Aquaporin-3 mRNA and Protein Expression. (Q38780199) (← links)
• Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions (Q39458847) (← links)
• Fumaric acid esters in dermatology. (Q42401921) (← links)
• Toll-Like Receptors: Role in Dermatological Disease (Q42431181) (← links)
• Ulcerated necrobiosis lipoidica as a rare cause for chronic leg ulcers: case report series of ten patients (Q45755633) (← links)
• Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects (Q46798016) (← links)
• Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells. (Q47194056) (← links)
• To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis. (Q47859915) (← links)
• Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study (Q48122586) (← links)
• Regulated genes in psoriatic skin during treatment with fumaric acid esters (Q57618936) (← links)
• Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis. (Q64885022) (← links)
• Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration (Q79771601) (← links)
• BG-12 and its potential for the prevention of relapse in multiple sclerosis (Q92489462) (← links)